What is Lifesci Capital’s Forecast for TECX FY2025 Earnings?

Tectonic Therapeutic, Inc. (NASDAQ:TECX) – Analysts at Lifesci Capital issued their FY2025 earnings estimates for Tectonic Therapeutic in a report issued on Thursday, February 5th. Lifesci Capital analyst G. Maini expects that the company will post earnings of ($4.72) per share for the year. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Tectonic Therapeutic’s current full-year earnings is ($8.31) per share. Lifesci Capital also issued estimates for Tectonic Therapeutic’s Q4 2025 earnings at ($1.21) EPS.

Tectonic Therapeutic (NASDAQ:TECX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($1.02) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.03.

Several other analysts have also weighed in on the stock. Truist Financial lowered their price objective on shares of Tectonic Therapeutic from $64.00 to $60.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Wells Fargo & Company initiated coverage on shares of Tectonic Therapeutic in a research note on Monday, October 20th. They issued an “overweight” rating and a $101.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tectonic Therapeutic in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $81.50.

Tectonic Therapeutic Stock Performance

Shares of TECX opened at $24.37 on Monday. The firm has a market cap of $456.21 million, a PE ratio of -6.31 and a beta of 3.71. Tectonic Therapeutic has a 52-week low of $13.70 and a 52-week high of $42.76. The business’s 50 day moving average price is $20.35 and its two-hundred day moving average price is $19.61.

Hedge Funds Weigh In On Tectonic Therapeutic

Large investors have recently bought and sold shares of the stock. Aberdeen Group plc grew its stake in shares of Tectonic Therapeutic by 220.6% in the 4th quarter. Aberdeen Group plc now owns 1,141,824 shares of the company’s stock worth $23,818,000 after acquiring an additional 785,648 shares in the last quarter. Braidwell LP purchased a new position in Tectonic Therapeutic during the third quarter worth about $11,561,000. Millennium Management LLC grew its position in Tectonic Therapeutic by 726.4% in the 1st quarter. Millennium Management LLC now owns 237,938 shares of the company’s stock worth $4,214,000 after purchasing an additional 209,145 shares in the last quarter. Kennedy Capital Management LLC bought a new stake in Tectonic Therapeutic in the 3rd quarter worth about $3,276,000. Finally, First Light Asset Management LLC purchased a new stake in Tectonic Therapeutic in the 3rd quarter valued at about $3,176,000. 62.63% of the stock is currently owned by institutional investors.

About Tectonic Therapeutic

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.